Sodium-glucose cotransporter 2 inhibitors in hospitalized heart failure patients: No time like now.

Publisher: Wiley Country of Publication: England NLM ID: 100887595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0844 (Electronic) Linking ISSN: 13889842 NLM ISO Abbreviation: Eur J Heart Fail Subsets: MEDLINE

Publication: 2014- : Chichester : Wiley
Original Publication: Amsterdam ; New York : Elsevier Science, c1999-

Heart Failure*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Diabetes Mellitus, Type 2*; Humans ; Canagliflozin ; Glucose ; Sodium

Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med 2022;28:568-574. https://doi.org/10.1038/s41591-021-01659-1.
Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 2019;73:2365-2383. https://doi.org/10.1016/j.jacc.2019.02.015.
Ferreira JP, Rossignol P, Machu JL, Sharma A, Girerd N, Anker SD, et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: Findings from BIOSTAT-CHF. Eur J Heart Fail 2017;19:1284-1293. https://doi.org/10.1002/ejhf.900.
Ferreira JP, Blatchford JP, Teerlink JR, Kosiborod MN, Angermann CE, Biegus J, et al. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE. Eur J Heart Fail 2023;25:1797-1805. https://doi.org/10.1002/ejhf.2982.
Shen L, Kristensen Søren L, Bengtsson O, Böhm M, de Boer RA, Docherty KF, et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists. JACC Heart Fail 2021;9:254-264. https://doi.org/10.1016/j.jchf.2020.11.009.
Yang M, Butt JH, Kondo T, Jering KS, Docherty KF, Jhund PS, et al. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. Eur J Heart Fail 2022;24:2307-2319. https://doi.org/10.1002/ejhf.2722.
Ferreira JP, Butler J, Zannad F, Filippatos G, Schueler E, Steubl D, et al. Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 2022;79:1129-1137. https://doi.org/10.1016/j.jacc.2022.01.029.
Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol 2021;77:1397-1407. https://doi.org/10.1016/j.jacc.2021.01.044.
Kalra R, Parcha V, Patel N, Bhargava A, Booker KS, Arora G, et al. Increased awareness, inadequate treatment, and poor control of cardiovascular risk factors in American young adults: 2005-2016. Eur J Prev Cardiol 2021;28:304-312. https://doi.org/10.1177/2047487320905190.
Kalra R, Patel N, Arora P, Arora G. Cardiovascular health and disease among Asian-Americans (from the National Health and Nutrition Examination Survey). Am J Cardiol 2019;124:270-277. https://doi.org/10.1016/j.amjcard.2019.04.026.
Shetty NS, Patel N, Gaonkar M, Kalra R, Li P, Pavela G, et al. Trends of cardiovascular health in Asian American individuals: A National Health and Nutrition Examination Survey study. Am J Prev Cardiol 2023;14:100509. https://doi.org/10.1016/j.ajpc.2023.100509.

0SAC974Z85 (Canagliflozin)
0 (Sodium-Glucose Transporter 2 Inhibitors)
IY9XDZ35W2 (Glucose)
9NEZ333N27 (Sodium)

Date Created: 20230904 Date Completed: 20231101 Latest Revision: 20231101

20231101

10.1002/ejhf.3022

37661932